BLA 761334/S-005

SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING REQUIREMENT

Incyte Corporation
Attention: Felicia Diggs, RN, BSN, MSN
Associate Director, Global Regulatory Affairs
1801 Augustine Cut-Off
Wilmington, DE 19803

Dear Felicia Diggs:

Please refer to your supplemental biologics license application (sBLA) received March 24, 2025, and your amendments, submitted under section 351(a) of the Public Health Service Act for Zynyz (retifanlimab-dlwr) injection, for intravenous use.

This Prior Approval supplemental biologics license application:

- updates the Zynyz (retifanlimab-dlwr) Prescribing Information with data from the Final Study Report of Study INCMGA 0012-201 entitled "A Phase 2 study of INCMGA00012 in Patients with Merkel Cell Carcinoma (POD1UM-201)." This Report was associated with postmarketing requirement (PMR) 4412-1 included in the March 22, 2023, approval letter.

- supports the conversion of accelerated approval under 21 CFR 601 Subpart E of the metastatic or recurrent locally advanced Merkel cell carcinoma indication to traditional approval.

APPROVAL

We have completed our review of this sBLA, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,[1] that is identical to the enclosed labeling (text for the Prescribing Information

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

and Medication Guide) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2] The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

SUBPART E FULFILLED

We approved this BLA under the regulations at 21 CFR 601 Subpart E for Accelerated Approval of Biological Products for Serious or Life-Threatening Illnesses. Approval of this supplement fulfills your commitments made under 21 CFR 601.41.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplement application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submission dated March 24, 2025, containing the final report for the following postmarketing requirement listed in the March 22, 2023, approval letter for BLA 761334.

4412-1 Conduct a multicenter clinical trial intended to confirm the clinical benefit of retifanlimab-dlwr in patients with metastatic or recurrent locally

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

advanced Merkel cell carcinoma (MCC) who have not received prior systemic therapies for metastatic or recurrent locally advanced MCC. The trial will enroll at least 100 patients to be followed for a minimum of 12 months to establish the objective response rate and characterize the durability of response. Include an analysis of overall survival, when 70% of patients have died, or all patients have been followed for at least three years.

We have reviewed your submission and conclude that the above requirement was fulfilled.

This closes all of your postmarketing requirements and postmarketing commitments acknowledged in our March 22, 2023, letter. You are not required to report on the status of closed (released or fulfilled) PMRs/PMC in your annual report required under 21 CFR 601.70.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*[3]

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.[4] Information and Instructions for completing the form can be found at FDA.gov.[5]

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 601.12(f)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(f)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

[3] For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
[4] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

If you have any questions, email Autumn Zack-Taylor, MS, Senior Regulatory Health Project Manager, at Autumn.Zack-Taylor@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Steven Lemery, MD, MHS
Director
Division of Oncology 3
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

STEVEN J LEMERY
12/17/2025 02:32:35 PM